[1]卫生部疾病预防控制局,卫生部医政司,中国疾病预防控制中心.中国结核病防治规划实施工作指南[M].北京:中国协和医科大学出版社,2009: 1.[2] World Health Organization (2008).Guidelines for the programmatic management of drug-resistant tuberculosis emergency update 2008[S]. Geneva: Switzerland.[3] World Health Organization/International Union Against Tuberculosis and Lung Disease (2007). Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world: report no4[R]. Geneva: Switzerland.[4] Moellering RC. Linezolid: the first oxazolidinone antimicrobial [J].Ann Intern Med, 2003,138(2):135-142.[5] Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC.In vitroactivities of linezolid against clinical isolates ofMycobacterium tuberculosiscomplex isolated in Taiwan over 10 years [J].Antimicrob Agents Chemother, 2008,52(6):2226-2227.[6] van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, Boeree MJ, van Soolingen D. Comparative study on genotypic and phenotypic second-line drug resistance testing ofMycobacterium tuberculosiscomplex isolates[J]. J Clin Microbiol,2010,48(8):2749-2753.[7] Ermertcan S, Hosgor-Limoncu M, Erac B, Tasli H, Cavusoglu C, Bozkurt H.In vitroactivity of linezolid againstMycobacterium tuberculosisstrains isoalted from Western Turkey[J]. Jpn J Infect Dis, 2009,62(5):384-385.[8] Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcón E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis[J]. Int J Tuberc Lung Dis,2005,9(6): 640-645.[9] Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP.Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis [J]. Lancet Infect Dis, 2009,9(3):153-161. [10]Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis[J]. PLoS One, 2009,4(9):e6914.[11] Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06[J].J Antimicrob Chemother,2010,65(4):775-783.[12] Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis[J]. Clin Infect Dis, 2010,50(1):49-55.[13] Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis[J]. Eur Respir J,2009,34(2):387-393.[14] Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, Shim TS. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis[J]. J Antimicrob Chemother, 2009,64(2):388-391.[15] von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases[J]. J Infect,2006,52(2):92-96.[16] Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, Codecasa LR, Spanevello A, Cirillo DM. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis[J]. Eur Respir J,2008,31(4): 904-905.[17] Migliori GB, Lange C, Centis R, Sotgiu G, Mütterlein R, Hoffmann H, Kliiman K, De Iaco G, Lauria FN, Richardson MD, Spanevello A, Cirillo DM. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases[J]. Eur Respir J, 2008,31(6): 1155-1159.[18] Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis[J]. Ther Drug Monit,2010,32(1):97-101.[19] Nannini EC, Keating M, Binstock P, Samonis G, Kontoyiannis DP. Successful treatment of refractory disseminatedMycobacteriumavium complex infection with the addition of linezolid and mefloquine[J]. J Infect, 2002,44(3):201-203.[20] Fortún J, Martín-Dávila P, Navas E, Pérez-Elías MJ, Cobo J, Tato M, De la Pedrosa EG, Gómez-Mampaso E, Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis[J]. J Antimicrob Chemother, 2005,56(1):180-185.[21] 中国防痨协会. 耐药结核病化学治疗指南(2009)[J].中华结核和呼吸杂志, 2010,33(7):485-497. |